Anna Durbin, MD
Center for Immunization Research (CIR), Johns Hopkins School of Public Health
16
15
16
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+16 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (16)
Showing 10 of 16 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Clemente Diaz, MD
University of Puerto Rico
Shared therapeutic areas:
Alberto Santiago-Cornier, MD
Department of Molecular Medicine
Shared therapeutic areas:
Jose Tavarez-Valle, MD
Private Practice, PR
Shared therapeutic areas:
Luis Rodriguez-Carrasquillo, MD
Private Practice, PR
Shared therapeutic areas:
Myrielle Dupont-Rouzeyrol, PhD
Institut Pasteur de Nouvelle-Calédonie
Shared therapeutic areas:
Clemente Diaz-Perez, MD
University of PR
Shared therapeutic areas:
Elisabeth Adderson, MD
St. Jude Children's Research Hospital
Shared therapeutic areas:
Nigel Hill, PhD
London School of Hygiene and Tropical Medicine
Shared therapeutic areas:
Evelyn Matta-Fontanet, MD
Caparra Internal Medicine Research Center
Shared therapeutic areas:
Miguel Sosa-Padilla, MD
Private Practice PR
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (16)
Showing 16 of 16 trials
Evaluating the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV005 to Protect Against Infection With rDEN3Δ30
Evaluating the Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TetraVax-DV) TV005 in Flavivirus-Naive Adults 50 to 70 Years of Age
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-4995) in Healthy Adults
Safety of and Immune Response of a 2-dose Regimen of rDEN1delta30 Dengue Virus Vaccine
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3-3'Ddelta30) in Healthy Adults
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31-7164) in Healthy Adults
Evaluation of the Safety and Immune Response of Five Admixtures of a Tetravalent Dengue Virus Vaccine
Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine
Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine
Evaluating the Safety and Immune Response to Two Doses of a Dengue Virus Vaccine Administered 12 Months Apart
Evaluating the Safety and Immune Response to a Dengue Virus Vaccine in Healthy Adults
Evaluating the Safety and Effectiveness of a Dengue Virus Vaccine in Healthy Adults
Evaluation of the Safety and Efficacy of a Single Dose of a Dengue Vaccine (TV005) in Healthy Adults
Evaluating the Clinical and Immune Response to Two Dengue Virus Vaccines in Healthy Adults
Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2
Evaluating the Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue Vaccine (V180) in Healthy Adults Who Previously Received a Live-Attenuated Tetravalent Vaccine (TV003 or TV005)
All 16 trials loaded